Abstract:Abstract Background: Myelosuppression is a common adverse effect in breast cancer patients receiving anthracyclines combined with cyclophosphamide chemotherapy. Screening potential biomarkers and building predictive models have implications for clinical management of myelosuppression. Methodology: This study collected 103 breast cancer patients in Shenzhen, China, from September 2020 to January 2022, including two different chemotherapy (Epirubicin or Doxorubicin). The plasma samples were collected 48 hours after chemotherapy. Plasma metabolomics were measured using Ultra-High-Performance Liquid Chromatography-Tandem Q-Exactive. After identification of metabolites and screening of potential differential metabolites, we mapped the key pathways. Further, we established a LASSO-logistic predictive model for myelosuppression. Results: In the group of patients treated with doxorubicin, we identified 19 differential metabolites. These metabolites were primarily associated with 6 metabolic pathways, including sphingolipid metabolic pathway, glycine, serine and threonine metabolic pathway, glycerol phospholipid metabolic pathway, tryptophan metabolic pathway, primary bile acid biosynthesis pathway and purine metabolic pathway. From these, a final logistic regression model was developed, incorporating seven variables. This model exhibited an accuracy of 84.91% in predicting chemotherapy-related myelosuppression, with an impressive area under the ROC curve of 0.9571. Similarly, in patients who received epirubicin, we uncovered 20 differential metabolites that were linked to 14 metabolic pathways, encompassing taurine and hypotaurine metabolism, D-glutamine and D-glutamic acid metabolism, and more. A final logistic regression model was constructed, encompassing 12 variables. This model demonstrated an accuracy of 82.35% in predicting the occurrence of chemotherapy-related myelosuppression, with an area under the ROC curve reaching 0.9198. Conclusion: In this study, potential biomarkers and metabolic pathways related to myelosuppression were screened by non-targeted metabolomics. The prediction models of myelosuppression in different chemotherapy populations was constructed, and the models demonstrated robust discriminatory and predictive capabilities. Our novel findings suggested that metabolomics provided unique insights into formulating individualized medication strategies for anthracyclines combined with cyclophosphamide in breast cancer patients.

Related Factors Analysis of Myelosuppression Caused by Antineoplastics

A Study of Novel Febrile Neutropenia Risk Factors Related to Bone Marrow or Immune Suppression, Barrier Function, and Bacterial Flora.

Clinical Analysis of Chemotherapy-induced Myelosuppression in Breast Cancer Patients

Analysis of Multiple Factors Related to Hematologic Toxicity Following 153Sm-Edtmp Therapy.

Preliminary Analysis on the Prognostic Factors of Long-term Myelosuppression in Patients With Ovarian Epithelial Cancer After Initial Treatment

Characteristics of Adverse Reactions of Antineoplastic Drugs in 787 Cases and the Prognosis Analysis

Association Between Single Nucleotide Polymorphisms (Snps) And Toxicity Of Advanced Non-Small-Cell Lung Cancer Patients Treated With Chemotherapy

Analysis of the Risk Factors for Myelosuppression after Concurrent Chemoradiotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Preliminary metabolomics-based predictive models for myelosuppression in breast cancer patients with different anthracycline chemotherapy

Genetic Associations of Docetaxel‐based Chemotherapy‐induced Myelosuppression in Chinese Han Population

Risk Factors Study for Lung Cancer Patients with Chemotherapy-induced Severe Neutropenia

Chemotherapy-Induced Myelosuppression in Esophageal Cancer Patients: Risks and Suggestions for Its Management

Chemotherapy-Induced Neutropenia During Adjuvant Treatment for Cervical Cancer Patients: Development and Validation of A Prediction Model

Safety Analysis of Antineoplastic Drugs for Lung Cancer: a Retrospective Analysis Based on Shaanxi Province in Western China

Analysis of risk factors of serious adverse drug reactions in chemotherapy of lung cancer patients

Meta-analysis of Risk Factors Associated with Oxaliplatin Hypersensitivity Reactions in Cancer Patients

Analysis of the relationship between chemotherapy-induced myelotoxicity and clinical efficacy in patients with early breast cancer

Genome-wide Association Study of Myelosuppression in Non-Small-cell Lung Cancer Patients with Platinum-Based Chemotherapy

Potential Determinants for Radiation-Induced Lymphopenia in Patients With Breast Cancer Using Interpretable Machine Learning Approach

Analysis of 422 cases adverse drug reactions of antineoplastic drugs

Analysis of 281 Adverse Drug Reaction Reports of Antineoplastics Drugs in Our Hospital